Julie Brahmer, MD
Enriched profileDirector, Thoracic Oncology Program; Professor of Oncology; Marilyn Meyerhoff Professor in Thoracic Oncology; Co-Director, Upper Aerodigestive Malignancies Division · Johns Hopkins University School of Medicine
Julie Brahmer is Director, Thoracic Oncology Program; Professor of Oncology; Marilyn Meyerhoff Professor in Thoracic Oncology; Co-Director, Upper Aerodigestive Malignancies Division at Johns Hopkins University School of Medicine. OpenAlex indexes 855 publications with 124,810 citations (h-index 116); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Julie Brahmer, MD, is Director, Thoracic Oncology Program at Johns Hopkins University School of Medicine / Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. The public record shows 855 publications with 124,810 citations (h-index 116), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 19 companies, 3 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 332.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202510 payments$10,407openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20254 payments
- Janssen Biotech, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.6%Kinase inhibitor35.5%Tagrisso70%Alecensa30%Part D<11 patientsOther antineoplastic agents14%Lumakras100%Part D<11 patientsMetabolism & gastrointestinal
19.8%Antidiarrheal microorganisms10.7%Folic Acid100%Part D<11 patientsProton pump inhibitor9.1%Pantoprazole Sodium100%Part D<11 patientsNervous system
19.8%Phenothiazine19.8%Prochlorperazine Maleate100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Johns Hopkins University NCTN Lead Academic Site Program
Johns Hopkins University
FY2025$522,793UG1CA233196 - Johns Hopkins University NCTN Lead Academic Site Program
Johns Hopkins University
FY2024$568,290UG1CA233196
Congress activity
Updated 27 Aug 2026
165 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 110: Clinical utility of landmark ctDNA molecular response as an early indicator of immunotherapy outcomes in lung cancer.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Clinical cancer research
Article2026 - Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.
Cancer research communications
Article2026 - Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Cancer research communications
Article2025 - Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer12,670 citations2012
- 02Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer10,124 citations2016
- 03
- 04
- 05Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer8,006 citations2012
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/julie-brahmer-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
julierbrahmermd.com
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →julierbrahmermd.com ↗ - ResearchGate
researchgate.net/profile/Julie-Brahmer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/society-for-immunotherapy-of-cancer-sitc_welcome-dr-julie-r-brahmer-of-johns-hopkins-activity-7358904922978832384-wXCf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Spotify
open.spotify.com/show/7nprrdMprgzQrH3phxaSIh
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - Other
iaslc.org/iaslc-news/lung-cancer-considered/seminal-trial-series-nivolumab-and-non-small-cell-lung-cancer-dr
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Chairman
Scientific Executive Committee, National Lung Cancer Partnership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member: ASCO
IASLC, AACR, SITC
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Awards & honors
honors on the public record- Paul A. Bunn
Jr. Scientific Award, IASLC (2024), lifetime achievement in thoracic cancer scientific research, presented at WCLC24
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ilcn.org ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Cancer Immunology Program, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Co-Principal Investigator
Johns Hopkins National Clinical Trials Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →julierbrahmermd.com ↗ - Director
Kimmel Cancer Center at Johns Hopkins Bayview campus
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →julierbrahmermd.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine
Constantine Lyketsos, MD
Johns Hopkins University School of Medicine